經歷

玉晟管理顧問股份有限公司副總經理
台灣東洋藥品抗重症產品發展事業群主管及副總經理
永昕生物醫藥股份有限公司董事長
金樺、台灣東曜、中美冠科有限公司董事

專長學科

感染症；臨床微生物學；分子微生物學； 企業管理 ；藥品開發

近年學術論文著作

1. Wang YC, Huang SW, Chiang MH, Lee IM, Kuo SC, Yang YS, Chiu CH, Su YS, Chen TL, Wang FD, Lee YT. In vitro and in vivo activities of imipenem combined with BLI-489 against class D β-lactamase-producing Acinetobacter baumannii. J Antimicrob Chemother. 2021 Jan 19;76(2):451-459. doi: 10.1093/jac/dkaa421.

2. Li LH, Yang YS, Sun JR, Huang TW, Huang WC, Chen FJ, Wang YC, Kuo TH, Kuo SC, Chen TL, Lee YT; ACTION study group. Clinical and molecular characterization of Acinetobacter seifertii in Taiwan. J Antimicrob Chemother. 2021 Jan 19;76(2):312-321. doi: 10.1093/jac/dkaa432.

3. Kang FY, How CK, Wang YC, Cheng A, Yang YS, Kuo SC, Liu CP, Liu YM, Chen TL, Lee YT. Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia. Antimicrob Resist Infect Control. 2020 Sep 29;9(1):160. doi:

4. Chiang MH, Yang YS, Sun JR, Wang YC, Kuo SC, Lee YT, Chuang YP, Chen TL. *Confronting Tigecycline-Resistant Acinetobacter baumannii via Immunization Against Conserved Resistance Determinants. Front Microbiol. 2020 Mar 31;11:536. doi: 10.3389/fmicb.2020.00536. eCollection 2020.

5. Lee YT, Sun JR, Wang YC, Chiu CH, Kuo SC, Chen TL; ACTION study group, Yang YS. Multicenter Study of the Risk Factors for Mortality in Patients with Acinetobacter Bacteremia Receiving Colistin Treatment. Int J Antimicrob Agents. 2020 Apr 9:105956. doi: 10.1016/j.ijantimicag.2020.105956. [Epub ahead of print]

6. Chang YY, Yang YS, Wu SL, Wang YC, Chen TL; ACTION study group, Lee YT. Comparison of Cefepime/Cefpirome and Carbapenem Therapy for Acinetobacter Bloodstream Infection: A Multicentre Study. Antimicrob Agents Chemother. 2020 Mar 16. pii: AAC.02392-19. doi: 10.1128/AAC.02392-19. [Epub ahead of print]

7. Chiu CH, Lee YT, Lin YC, Kuo SC, Yang YS, Wang YC, Liu YH, Lin JC, Chang FY, Chen TL*. Bacterial membrane vesicles from Acinetobacter baumannii induced by ceftazidime are more virulent than those induced by imipenem. Virulence. 2020 Dec;11(1):145-158. doi: 10.1080/21505594.2020.1726593.

8. Wang YC, Ku WW, Yang YS, Kao CC, Kang FY, Kuo SC, Chiu CH, Chen TL, Wang FD, Lee AY. Is Polymicrobial Bacteremia an Independent Risk Factor for Mortality in Acinetobacter baumannii Bacteremia? J Clin Med. 2020 Jan 6;9(1). pii: E153. doi: 10.3390/jcm9010153.

9. Yang YS, Chen HY, Hsu WJ, Chou YC, Perng CL, Shang HS, Hsiao YT, Sun JR; ACTION study group. Overexpression of AdeABC efflux pump associated with tigecycline resistance in clinical Acinetobacter nosocomialis isolates. Clin Microbiol Infect. 2019 Apr;25(4):512.e1-512.e6.

10. Liu YH, Kuo SC, Yao BY, Fang ZS, Lee YT, Chang YC, Chen TL*, CMJ Hu *. Colistin nanoparticle assembly by coacervate complexation with polyanionic peptides for treating drug-resistant gram-negative bacteria. Acta Biomater. 2018 Dec;82:133-142.

11. Lee Y, Lee YT, Wang YC, Chen CT, Sun JR, Liu CP, Liu YM, Kuo SC, Chiu CH, Yang YS, Lin JC, Chen TL. Risk of Mortality of Catheter-Related Bloodstream Infections Caused by Acinetobacter Species: Is Early Removal of the Catheters Associated With a Better Survival Outcome? J Intensive Care Med. 2018 Jun;33(6):361-369.

12. Lee IM, Yang FL, Chen TL, Liao KS, Ren CT, Lin NT, Chang YP, Wu CY, Wu SH. Pseudaminic acid on exopolysaccharide of Acinetobacter baumannii plays a critical role in phage-assisted preparation of glycoconjugate vaccine with high antigenicity. J Am Chem Soc. 2018 Jul 18;140(28):8639-8643.

13. Wang YC, Huang TW, Yang YS, Kuo SC, Chen CT, Liu CP, Liu YM, Chen TL, Chang FY, Wu SH, How CK, Lee YT. Biofilm formation is not associated with worse outcome in Acinetobacter baumannii bacteraemic pneumonia. Sci Rep. 2018 May 8;8(1):7289.

14. Liu CP, Chiang TT, Liu YM, Kuo SC, Yang YS, Lee YT, Chen TL, Shih SC; ACTION Study Group. A multicenter study on clinical characteristics of Acinetobacter bacteremia in patients with liver cirrhosis. J Microbiol Immunol Infect. 2018 Apr 25. pii: S1684-1182(18)30070-7.

15. Chang YY, Liu YM, Liu CP, Kuo SC, Chen TL; ACTION study group. Impact of reduced tigecycline susceptibility on clinical outcomes of Acinetobacter bacteremia. J Microbiol Immunol Infect. 2018 Feb;51(1):148-152.

16. Kuo SC, Huang WC, Huang TW, Wang HY, Lai JF, Chen TL, Lauderdale TL. Molecular Epidemiology of Emerging blaOXA-23-Like- and blaOXA-24-Like-Carrying Acinetobacter baumannii in Taiwan. Antimicrob Agents Chemother. 2018 Mar; 62(3): e01215-17.
 
17. Chang YY, Liu YM, Liu CP, Kuo SC, Chen TL; ACTION study group. Impact of reduced tigecycline susceptibility on clinical outcomes of Acinetobacter bacteremia. J Microbiol Immunol Infect. 2018 Feb;51(1):148-152. doi: 10.1016/j.jmii.2017.08.024. Epub 2017 Oct 7.

18. Chiang MH, Wu HH, Shih CJ, Chen YT, Kuo SC, Chen TL. Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients. Am Heart J. 2017 Nov;193:1-7. doi: 10.1016/j.ahj.2017.07.020. Epub 2017 Aug 2.

19. Yang YS, Wang YC, Kuo SC, Chen CT, Liu CP, Liu YM, Chen TL, Lee YT. Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia. Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00661-17.

20. Wu MS, Collier S, Liu PY, Lee YT, Kuo SC, Yang YS, Chen TL, Shi ZY, Lin CF. Sensitivity and specificity of Matrix-Associated Laser Desorption/Ionization - Time of Flight Mass Spectrometry (MALDI-TOF MS) in discrimination at species level for Acinetobacter bacteremia. J Microbiol Methods. 2017 Jun 29;140:58-60. doi: 10.1016/j.mimet.2017.06.019. [Epub ahead of print]

21. Lee YT, Wang YC, Kuo SC, Chen CT, Liu CP, Liu YM, Chen TL, Yang YS. Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy. Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00931-17.

22. Chen CT, Wang YC, Kuo SC, Shih FH, Chen TL, How CK, Yang YS, Lee YT. Community-acquired bloodstream infections caused by Acinetobacter baumannii: A matched case-control study. J Microbiol Immunol Infect. 2017 Jun 29. pii: S1684-1182(17)30106-8. doi: 10.1016/j.jmii.2017.02.004.